Fyarro is owned, manufactured, and commercialized by Aadi Bioscience, a precision oncology company dedicated to developing therapies tailored for genetic alterations in the mTOR pathway. Fyarro, which is an albumin-bound nanoparticle formulation of sirolimus approved for the treatment of advanced malignant perivascular epithelioid cell tumors, represents a core proprietary asset developed and marketed through the company's internal commercial infrastructure and clinical research network.